 | | Vol. 9.03 – 27 January, 2021 |
| |
|
|
| Using a robust in vitro Ebola virus pseudo-particle infection assay and a well-defined set of solid-phase assays, scientists describe a wide spectrum of antibody responses in a cohort of healthy survivors of the Sierra Leone Ebola virus outbreak of 2013–2016.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors performed a whole-blood preserving single-cell analysis protocol to integrate contributions from all major cell types including neutrophils, monocytes, platelets, lymphocytes and the contents of serum.
[Nature] |
|
|
|
| Investigators present a two-component protein-based nanoparticle vaccine that displayed multiple copies of the SARS-CoV-2 spike protein.
[Cell] |
|
|
|
| In mild COVID-19, CD8+ resident-memory and CD4+ T-helper-17 cells underwent active expansion towards the end of the trajectory, and were characterized by good effector functions, while in critical COVID-19 they remain more naïve.
[Cell Research] |
|
|
|
| Scientists characterized the immunoglobulin A (IgA) response to SARS-CoV-2 in a cohort of 149 convalescent individuals after diagnosis with COVID-19. IgA responses in plasma generally correlated with IgG responses.
[Science Translational Medicine] |
|
|
|
| To define immune-selected mutations in the SARS-CoV-2 spike (S) protein, researchers exposed a VSV-eGFP-SARS-CoV-2-S chimeric virus, in which the VSV glycoprotein was replaced with the S protein, to 19 neutralizing monoclonal antibodies against the receptor-binding domain.
[Cell Host & Microbe] |
|
|
|
| The authors compared the critical residues in the receptor-binding domain used by multiple neutralizing antibodies and cocktails and identified a combination of two antibodies CoV2-06 and CoV2-14 for preventing viral escape.
[Nature Communications] |
|
|
|
| Investigators report that SARS-CoV-2 infection in rhesus macaques, either infused with convalescent plasma, normal plasma, or receiving no infusion, resulted in transient accumulation of pro-inflammatory monocytes and proliferating T follicular helper (Th1) cells with a Th1 profile in peripheral blood.
[Nature Communications] |
|
|
|
| Researchers studied blood and airways of COVID-19 patients across disease severity at multiple timepoints. Monocytic myeloid-derived suppressor cells frequencies were elevated in blood but not in nasopharyngeal or endotracheal aspirates of COVID-19 patients compared to controls.
[Journal of Clinical Investigation] |
|
|
|
| Scientists interrogated the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death.
[Cell Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Investigators identified a role for antibody–microbe interactions in shaping a community of bacteria with an enhanced capacity to metabolize L-tyrosine.
[Nature Immunology] |
|
|
|
| The authors identified the mitochondrial protein ERA G-protein-like 1 as a mitochondrial antiviral signaling protein-interacting protein by using proximity-based labeling technology.
[Cell Reports] |
|
|
|
| Scientists used influenza virus to induce predominantly tissue resident memory T cells or cytomegalovirus to elicit a large pool of effector-like memory cells in the lungs and determined their early protective capacity and mechanism of reactivation.
[Mucosal Immunology] |
|
|
|
|
| Researchers discuss recent advances that underscore the importance of plasmids in bacterial ecology and evolution beyond horizontal gene transfer.
[Nature Reviews Microbiology] |
|
|
|
| Investigators compare recent high-resolution X-ray and cryoelectron microscopy structures of RNA polymerases of negative-sense RNA viruses with segmented and non-segmented genomes.
[Nature Reviews Microbiology] |
|
|
|
| The author updates concepts informing how metabolic disorders and their comorbidities modify the susceptibility to, natural history and potential treatment of SARS-CoV-2 infection, with a focus on human biology.
[Cell Metabolism] |
|
|
|
|
| Eli Lilly and Company, Vir Biotechnology, Inc. and GlaxoSmithKline plc. announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.
[Eli Lilly and Company (Globe Newswire, Inc.)] |
|
|
|
| Immutep Limited announced that an independent Data and Safety Monitoring Board has completed a safety run-in data review of the first six patients from the Phase II clinical trial of Eftilagimod Alpha Treatment by immune modulation in COVID-19 disease, being conducted by the University Hospital Pilsen, Czech Republic.
[Immutep Limited (Globe Newswire, Inc.)] |
|
|
|
| Moderna, Inc. confirmed that the Company is in discussion with the US government to purchase an additional 100 million doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021.
[Moderna, Inc. (BusinessWire, Inc)] |
|
|
|
|
| February 8 – 9, 2021
Virtual |
|
|
|
|
|
| | University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| | Salk Institute of Biological Studies – La Jolla, California, United States |
|
|
|
| | University of Strasbourg – Strasbourg, France |
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
| | Stanford School of Medicine – Stanford, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
